COVID-19 as part of the hyperferritinemic syndromes: the role of iron depletion therapy
Interpretive Synthesis Review Article
[키워드] addition
Adult-onset Still’s disease
Anti-viral
association
asymptomatic patient
catastrophic
Catastrophic antiphospholipid syndrome
characterized
clinical picture
conditions
COVID-19
COVID-19 pandemic
COVID-19 patient
cytokine release
Deferoxamine
demonstrated
develop
disease
elevated
ferritin
fibrosis
hemophagocytic lymphohistiocytosis
Hyperferritinemia
Hyperferritinemic
IL-6
immunomodulatory effect
inflammatory process
iron
iron chelation
Iron depletion therapy
life-threatening
lymphopenia
macrophage activation syndrome
Mortality
Numerous
occur
other disease
pathogenic
SARS-CoV-2
SARS-COV-2 infection
Septic shock
severe pulmonary involvement
sustained
syndrome
Therapeutic approach
therapy
tissues
Treatment
[DOI] 10.1007/s12026-020-09145-5 PMC 바로가기 [Article Type] Interpretive Synthesis Review Article
[DOI] 10.1007/s12026-020-09145-5 PMC 바로가기 [Article Type] Interpretive Synthesis Review Article